Promises, Deceit and White-Collar Criminality Within the Theranos Scandal

Theranos rose to prominence by selling a dream that a company could make blood testing less painful and more effective. The company strove to bring new technology to the laboratory industry that would make Americans healthier. After securing more than $700 million from investors, Theranos would even...

Full description

Saved in:
Bibliographic Details
Published inJournal of white collar and corporate crime Vol. 3; no. 2; pp. 109 - 121
Main Author Griffin, O. Hayden
Format Journal Article
LanguageEnglish
Published Los Angeles, CA SAGE Publications 01.06.2022
Sage Publications Ltd
Subjects
white collar crime
corporate crime
business crime
Online AccessGet full text

Cover

More Information
Summary:Theranos rose to prominence by selling a dream that a company could make blood testing less painful and more effective. The company strove to bring new technology to the laboratory industry that would make Americans healthier. After securing more than $700 million from investors, Theranos would eventually receive, at its height, a $9 billion company valuation. As it turned out, Theranos and its founder, Elizabeth Holmes, had mainly promised innovations predicated on proprietary technology that did not work. Eventually, Holmes, and former company president Ramesh Balwani, would be charged with fraud both by the SEC and the federal government. The Theranos scandal has multiple dimensions that make it an interesting case study for white-collar and corporate crime.
ISSN:2631-309X
2631-3103
DOI:10.1177/2631309X20953832